Literature-Based Review of Multimodal Analgesic Approaches in Breast Reconstruction Revision

Collin B. George, pre-medical student ORCID: 0009-0007-8162-6839 Narrative Literature Review — repository release 2026.11 (text October 2026; source-currency update November 2026) License: CC BY 4.0

Educational work by a pre-medical student — not medical advice. Not a clinical protocol, prescription, or patient handout, and not for patient care. See DISCLAIMER.

Scope and Role-Boundary Statement

This document is an independent educational literature synthesis prepared for academic portfolio purposes. It is not a clinical protocol, institutional guideline, order set, or decision-support tool. It does not constitute medical advice and is not intended to guide patient care, replace attending physician judgment, or function as a perioperative documentation template of any kind.

All perioperative planning, anesthetic decision-making, medication selection, regional anesthesia technique, and postoperative management are the responsibility of the appropriately qualified treating team, subject to applicable scope-of-practice and institutional requirements. The discussion below is observational and analytical in character. It describes themes, considerations, and frameworks reported in published literature. It does not rank, recommend, or endorse any specific approach for any specific patient.

This document is not affiliated with, endorsed by, reviewed by, or issued on behalf of any healthcare, academic, or professional organization.

Purpose

This review examines published literature on analgesic and anesthetic approaches in post-mastectomy breast implant revision surgery, with particular attention to opioid-sparing, multimodal, and regional anesthesia frameworks as discussed in current perioperative literature. The goal is to understand how the literature characterizes the comparative considerations, potential advantages, reported limitations, and patient-specific factors associated with different perioperative analgesic strategies in this setting.

This is not an attempt to synthesize a clinical pathway. It is an effort to understand the reasoning clinicians and researchers use when evaluating perioperative options — and to analyze how evidence quality, patient heterogeneity, and institutional variability shape those discussions.

Methods Note

This work is a narrative literature review rather than a systematic review or formal meta-analysis. No PRISMA framework was applied, and source identification was not exhaustive.

Literature was identified through searches of PubMed using combinations of terms including "breast reconstruction," "implant revision," "regional anesthesia," "PECS block," "opioid-sparing anesthesia," "opioid-free anesthesia," "PONV," "multimodal analgesia," and "enhanced recovery after surgery," supplemented by society guidance and reference tracking. Priority was given to society guidance, systematic reviews, randomized trials, and perioperative publications most directly relevant to breast surgery and reconstruction settings. The documented search strings used for the companion manuscript are reported in George-BreastRecon-Review-v8.md.

Evidence quality across sources is heterogeneous. Where possible, guideline-level evidence is distinguished from trial-level evidence and expert opinion, though this review does not apply a formal evidence-grading framework. Where direct evidence specific to breast reconstruction revision was limited, adjacent surgical literature was interpreted cautiously and identified as extrapolative where applicable. Readers should consult primary sources and institutional resources for any clinical purpose.

Source-currency note (November 2026). Superseded guidance is cited as historical. The 2020 PROSPECT breast guideline (Jacobs et al., 2020) has a 2026 update for major oncological breast surgery (Desai et al., 2026). The Fourth PONV consensus (Gan et al., 2020) has been replaced by the Fifth (Gan et al., 2025). The fourth-edition ASRA antithrombotic guideline (Horlocker et al., 2018) has been replaced by the fifth edition (Kopp et al., 2025). For the 2025–2026 documents only abstracts and summaries were reviewed.

Background and Clinical Context

Post-mastectomy breast implant revision surgery encompasses a range of procedures including capsular contracture management, implant exchange, pocket revision, and infection-related explantation and reimplantation. These procedures present perioperative management considerations that have attracted substantial literature interest, particularly regarding analgesic strategy, postoperative nausea and vomiting (PONV) prevention, and recovery quality.

The published literature on this topic intersects several active areas of perioperative medicine: enhanced recovery after surgery (ERAS) pathways, opioid stewardship, regional anesthesia expansion, and multimodal analgesia. Understanding how these intersect in the context of breast reconstruction revision is the organizing question of this review.

Perioperative management in this setting involves collaboration across surgical, anesthesia, and nursing teams. Decisions about analgesic strategy, regional technique, and postoperative monitoring are highly individualized and institution-dependent. The discussion below reflects how these decisions are framed in the published literature — not how they should be made in any specific clinical context.

Section 1: Multimodal Analgesia — Conceptual Framework

1.1 General Principles in Published Literature

ERAS-aligned literature commonly describes multimodal analgesia as a foundational concept in perioperative pain management (Temple-Oberle et al., 2017; Jacobs et al., 2020). The core principle, as articulated in these publications, is that combining analgesic agents with different mechanisms of action may reduce reliance on any single agent class — including opioids — while maintaining or improving analgesia quality.

Agents commonly discussed in the multimodal analgesia literature for breast surgery settings include acetaminophen, NSAIDs and COX-2 inhibitors, alpha-2 agonists (dexmedetomidine), NMDA receptor antagonists (ketamine), sodium channel modulators (intravenous lidocaine), regional anesthetics, and glucocorticoids (dexamethasone). The evidence base for individual agents varies considerably in depth and consistency across published studies.

1.2 ERAS Society Guidance

An ERAS Society–endorsed consensus review for breast reconstruction recommends opioid-sparing perioperative medications, anesthetic techniques that decrease PONV and pain, minimal preoperative fasting, prevention of intraoperative hypothermia, and early mobilization (Temple-Oberle et al., 2017). The review notes that most of its recommendations rest on lower-level or extrapolated evidence. The 2020 PROSPECT guideline for oncological breast surgery, now historical, similarly recommended basic non-opioid analgesics and reserved opioids for rescue. For major breast surgery it named paravertebral block as the first-choice regional technique, PECS block as an alternative to it, and wound infiltration as an addition to a regional technique (Jacobs et al., 2020). Its 2026 update for major oncological breast surgery continues to recommend paracetamol, NSAIDs or COX-2 inhibitors and dexamethasone. It lists several single-shot regional techniques (erector spinae plane, PECS, serratus anterior plane and paravertebral blocks) and local infiltration analgesia as recommended (Desai et al., 2026; abstract only reviewed). The 2020 guideline also recommended preoperative gabapentin. A later mixed-surgery meta-analysis did not support routine gabapentinoid use (Verret et al., 2020), and gabapentinoids are not among the interventions recommended in the 2026 abstract. Applicability to specific patients and procedures requires individualized clinical judgment by the treating team and integration with local institutional protocols.

1.3 Evidence Heterogeneity

A limitation noted across the literature is heterogeneity in study populations, outcome definitions, analgesic combinations, and institutional practices. Findings from one institutional or procedural context do not translate automatically to others. This review reflects that heterogeneity and does not attempt to resolve it through synthesis of a single approach.

Section 2: Regional Anesthesia for Breast Surgery

2.1 Pectoral Nerve Blocks (PECS I and II)

The PECS I block was first described by Blanco in 2011, and the PECS II ("modified Pecs") block in 2012 (Blanco, 2011; Blanco et al., 2012). Both have been the subject of substantial literature interest in breast surgery analgesia. PECS I targets the lateral and medial pectoral nerves in the fascial plane between pectoralis major and pectoralis minor. PECS II adds a deeper injection intended to block at least the pectoral nerves, the intercostobrachial nerve, intercostal nerves III–VI, and the long thoracic nerve (Blanco et al., 2012).

Meta-analyses and trials describe opioid-sparing effects associated with PECS blocks in breast cancer surgery, although effect size, certainty, and generalizability vary across studies (Hussain et al., 2019; Sun et al., 2020; Bashandy & Abbas, 2015). A SAMBA practice advisory recommends PECS blocks over systemic analgesia alone for breast-conserving surgery but does not recommend them over surgeon-performed local infiltration. For mastectomy it recommends a PECS block if a patient is unable to receive a paravertebral block, which places PECS behind PVB (Ardon et al., 2022). The 2026 ASA practice guideline strongly recommends fascial plane blocks or paravertebral block for adults undergoing mastectomy, to reduce pain and/or opioid use in the first 24 hours (American Society of Anesthesiologists Task Force on Perioperative Pain Management, 2026). Dexamethasone as a perineural adjuvant has been reported in a meta-analysis of peripheral nerve block trials to prolong analgesia, although results were highly heterogeneous; evidence specific to PECS techniques is limited relative to the broader peripheral nerve block literature (Albrecht et al., 2015).

2.2 Serratus Anterior Plane Block

The serratus anterior plane (SAP) block has been described as an alternative or complement to PECS II, with reported coverage of the lateral chest wall. Published evidence for the SAP block includes data from thoracic surgery populations — including Kim et al. (Anesthesia & Analgesia, 2018), a randomized trial that evaluated the block in video-assisted thoracic surgery patients — and extrapolation to breast reconstruction revision settings remains indirect. A network meta-analysis in breast cancer surgery found SAP, PECS II, paravertebral, erector spinae plane, and rhomboid intercostal blocks all associated with lower pain and opioid use than no block, with very low strength of evidence for ranking among them (An et al., 2023).

2.3 Reported Considerations and Limitations

Published literature discusses several considerations relevant to regional anesthesia in this setting.

Local anesthetic systemic toxicity (LAST) is a recognized risk with large-volume regional techniques. ASRA Pain Medicine's practice advisory and checklist on LAST prevention, recognition, and management serve as widely used reference frameworks for this topic, and include lipid emulsion resuscitation as part of preparedness (Neal et al., 2018; Neal et al., 2021).

Bilateral procedures require attention to cumulative local anesthetic exposure. Foo et al. (2021) advise against overlapping IV lidocaine with the period of action of other local-anesthetic interventions, including regional blocks. This is more restrictive than simply adding doses together. No combination regimen or timing instruction is supplied here; see REFERENCE_AUDIT.md.

Patient-specific factors including coagulopathy, anticoagulation status, local infection, and anatomic variation are described in the literature as relevant to regional anesthesia eligibility, with ASRA Pain Medicine's antithrombotic guidelines serving as a primary reference framework. The current version is the fifth edition (Kopp et al., 2025), which, among other changes, describes anticoagulant dosing as "low" or "high" dose rather than "prophylactic" or "therapeutic". The fourth edition (Horlocker et al., 2018) is historical. No timing intervals are given in this review.

Section 3: Opioid-Sparing and Opioid-Free General Anesthesia

3.1 Conceptual Framing in the Literature

Opioid-free anesthesia (OFA) and opioid-sparing anesthesia (OSA) are terms used with some variability across publications to describe approaches that minimize or eliminate intraoperative opioid administration in favor of non-opioid analgesic combinations (Beloeil, 2019). Beloeil describes OFA as feasible but notes that the literature on clinically meaningful patient benefit, and on the side effects or complications that may accompany it, is still scarce.

The rationale discussed in published literature includes potential reduction in opioid-related adverse effects — particularly PONV, respiratory depression, and opioid-induced hyperalgesia — as well as alignment with opioid stewardship principles. Whether these benefits are realized in specific clinical contexts depends on patient selection, analgesic combination, and institutional factors.

3.2 Intravenous Analgesic Adjuncts

Several intravenous agents are discussed in the perioperative literature as components of opioid-sparing frameworks:

Dexmedetomidine is an alpha-2 agonist with sedative, anxiolytic, and analgesic-sparing properties (Weerink et al., 2017). A meta-analysis of perioperative alpha-2 agonists reported reduced 24-hour morphine consumption with dexmedetomidine and an increased risk of postoperative bradycardia (Blaudszun et al., 2012). The balance of potential analgesic benefit against hemodynamic effects is described as patient-specific and requiring attending-level clinical judgment.

Intravenous lidocaine infusion is discussed as having analgesic and opioid-sparing properties in several surgical contexts (McCarthy et al., 2010). Meta-analytic evidence shows benefit mainly in abdominal surgery; toxic plasma levels were observed in some trials, and the authors called for dose and safety to be established (Vigneault et al., 2011). Evidence specific to breast surgery is limited. An international consensus statement regards IV lidocaine as a high-risk medicine and advises that it should not be given at the same time as, or within the period of action of, other local anesthetic interventions such as regional blocks or infiltration (Foo et al., 2021; see Section 2.3).

Ketamine at subanesthetic doses is an NMDA antagonist. A Cochrane review concluded that perioperative IV ketamine probably reduces postoperative analgesic consumption and pain intensity across a range of operations, including mastectomy (Brinck et al., 2018). Cautions commonly described for ketamine include psychiatric history such as psychosis and conditions in which increases in blood pressure or heart rate would be hazardous.

3.3 Propofol Total Intravenous Anesthesia

Propofol-based TIVA is discussed in published literature as associated with reduced PONV compared with volatile anesthetic maintenance, and consensus PONV guidelines address anesthetic technique as part of reducing baseline PONV risk (Gan et al., 2020, historical; Gan et al., 2025). The breast reconstruction ERAS review recommends anesthetic techniques that decrease PONV and pain (Temple-Oberle et al., 2017). This review did not confirm a specific recommendation for propofol TIVA in that document. The attending team determines appropriateness for individual patients.

Section 4: Opioid-Inclusive Approaches — Reported Context

4.1 Continued Role in Selected Populations

Published literature does not characterize opioid-inclusive anesthesia as categorically suboptimal in all contexts. The 2020 procedure-specific guidance for oncological breast surgery reserved opioids for postoperative rescue analgesia rather than excluding them (Jacobs et al., 2020). In the author's reading, opioid-containing approaches remain a recognized option in populations such as patients on chronic opioid therapy, those with multiple contraindications to non-opioid adjuncts, and those in whom opioid-sparing strategies have previously proven inadequate.

Inadequate pain management in patients with opioid tolerance carries its own patient safety implications, and coordination with chronic prescribers and pain management specialists is generally described as important in these contexts.

4.2 Opioid Minimization Within Conventional Approaches

Even within opioid-containing frameworks, published ERAS and fast-track literature commonly discusses opioid minimization principles, including reduced opioid exposure where feasible, combination with non-opioid multimodal adjuncts, adequate analgesia, and prophylaxis against nausea and vomiting (Kehlet & Wilmore, 2008; White et al., 2007; Temple-Oberle et al., 2017). This framing reflects the broader opioid stewardship orientation present throughout contemporary perioperative literature.

4.3 PONV in Opioid-Inclusive Contexts

Postoperative opioid use is one of the four predictors in the Apfel simplified risk score, alongside female sex, history of motion sickness or PONV, and non-smoking (Apfel et al., 1999). The Apfel score is among the most widely referenced PONV risk stratification tools in perioperative guidelines, and consensus publications describe multi-agent PONV prophylaxis scaled to risk (Gan et al., 2020, historical; Gan et al., 2025).

Section 5: Comparative Considerations Reported in the Literature

5.1 How Authors Frame the Comparison

Published literature discussing the comparison between opioid-sparing and opioid-inclusive approaches generally does not present a binary choice, but rather a spectrum of approaches calibrated to patient-specific factors. The framing in ERAS-aligned and procedure-specific publications is that regional and multimodal approaches are broadly discussed as potentially advantageous where feasible, with opioids retained for rescue or when opioid-sparing approaches are contraindicated, declined by patients, or technically not possible (Jacobs et al., 2020; Desai et al., 2026; Temple-Oberle et al., 2017).

5.2 Factors Discussed as Relevant in the Literature

Across ERAS-aligned and perioperative review literature, commonly discussed patient and procedural factors relevant to analgesic approach considerations in this setting include (Temple-Oberle et al., 2017; Jacobs et al., 2020; Desai et al., 2026; Gan et al., 2025; Kopp et al., 2025):

PONV risk profile and individual risk factors
Coagulopathy or anticoagulation status as relevant to regional anesthesia feasibility
Chronic opioid use and tolerance
Comorbidities including obstructive sleep apnea, hepatic dysfunction, renal impairment, and cardiac conditions
Procedure complexity and anticipated dissection extent
Patient preferences regarding needle-based procedures
Institutional formulary, local anesthetic availability, and regional anesthesia expertise

These factors are discussed in the literature as informing individualized clinical decision-making under attending supervision. They are presented here as educational context, not as a decision framework.

5.3 Recovery Outcomes Discussed in the Literature

Published studies examining opioid-sparing perioperative approaches in breast surgery contexts generally report outcomes including postoperative pain scores, PONV incidence, opioid consumption, time to discharge readiness, and patient satisfaction. Effect sizes and confidence in findings vary across studies depending on design quality, population characteristics, and outcome definitions. Readers are directed to primary sources for specific outcome data.

5.4 Important Uncertainties

Several important uncertainties are noted across the literature:

Many studies are conducted at centers with specific regional anesthesia expertise; generalizability to other settings is uncertain
Patient populations vary substantially across studies in terms of comorbidity burden, procedure complexity, and baseline opioid exposure
Outcome definitions — particularly for PONV and "opioid-free" — are inconsistent across publications
Long-term outcomes beyond the immediate perioperative period are less well-characterized
Optimal combinations of multimodal agents and their relative contributions remain subjects of ongoing investigation

Section 6: PONV — Literature Summary

PONV is discussed extensively in the perioperative breast surgery literature as a clinically important outcome affecting patient comfort, recovery quality, and resource utilization. The Apfel simplified risk score is among the most widely cited risk stratification tools in this context (Apfel et al., 1999; Gan et al., 2020). The current consensus is the Fifth (Gan et al., 2025). Its executive summary describes baseline risk assessment, prophylaxis scaled to risk, other risk-mitigation strategies and rescue, with added attention to post-discharge nausea and vomiting. The statements below that are attributed to the Fourth consensus (Gan et al., 2020) are historical and were not re-checked against the full Fifth consensus.

Published consensus guidelines describe a tiered prophylaxis approach in which the number and combination of preventive agents are scaled to patient risk level. Agents discussed include 5-HT3 antagonists, glucocorticoids, neurokinin-1 antagonists, and transdermal scopolamine, among others. The general principle across published rescue antiemetic discussions is to avoid repeating the same drug class in sequential rescue attempts (Gan et al., 2020).

The relationship between anesthetic technique and PONV is discussed in terms of both opioid minimization and propofol TIVA, both of which are associated with reduced PONV in published literature compared with opioid-containing volatile anesthesia in high-risk populations (Gan et al., 2020).

Section 7: Special Population Considerations in the Literature

Except for the obstructive sleep apnea paragraph, which cites an ASA guideline, this section is unsourced general background written by the author. It is not a literature summary, and readers should consult primary sources. Perioperative safety guidance commonly identifies several patient populations as requiring additional consideration in analgesic planning:

Elderly and frail patients are generally described as having increased sensitivity to sedative and analgesic agents, higher delirium risk, and reduced hepatic and renal clearance, making dose consideration and postoperative monitoring important. Processed EEG monitoring is discussed in some publications as potentially useful for anesthetic depth titration in this population.

Patients with obstructive sleep apnea are a population in whom opioid-related respiratory depression risk may be elevated. The American Society of Anesthesiologists has published practice guidelines on the perioperative management of these patients, including postoperative monitoring (American Society of Anesthesiologists Task Force on Perioperative Management of Patients with Obstructive Sleep Apnea, 2014).

Patients on chronic opioid therapy are generally discussed in terms of tolerance, opioid-induced hyperalgesia, and the importance of perioperative analgesic planning that accounts for baseline opioid requirements. Coordination with prescribing clinicians is described as important in this context.

Patients with opioid use disorder in recovery are generally discussed with attention to the ethical dimensions of opioid exposure in the perioperative setting, the potential value of opioid-sparing approaches where feasible, and the importance of involving addiction medicine or recovery support resources.

These population-specific considerations are summarized for educational purposes only.

Section 8: Limitations of This Review

This review has several important limitations that readers should consider.

This is a narrative literature review, not a systematic review. Source identification was not exhaustive, and no formal evidence-grading framework was applied. The review reflects the author's educational synthesis of available literature and should not be treated as a comprehensive or authoritative evidence assessment.

The author is a pre-medical student without clinical licensure or authority to provide clinical guidance. Interpretations reflect educational engagement with published sources rather than professional clinical judgment.

Evidence quality across the sources reviewed is heterogeneous. Guideline recommendations, randomized trial findings, observational data, and expert opinion are discussed without consistent formal grading. Readers should consult primary sources and qualified clinicians for any clinical purpose.

Institutional variability is substantial. Perioperative practices, formulary availability, regional anesthesia expertise, and patient populations vary across institutions in ways that significantly affect the applicability of any published findings. Nothing in this review should be read as applicable to any specific institution, clinical context, or patient population.

This review reflects literature identified through 2025. Reference identities were checked in October 2026, and superseded guidance was updated in November 2026. The perioperative medicine literature evolves continuously, and subsequent publications may modify or supersede the discussions summarized here.

Conclusion

The published perioperative literature on breast reconstruction revision surgery reflects an active and evolving discussion about analgesic strategy, PONV prevention, regional anesthesia integration, and recovery optimization. Several themes recur across sources: the potential advantages of opioid-sparing and multimodal approaches in appropriately selected patients, the importance of regional anesthesia expertise and patient-specific selection in realizing those advantages, the retained role of opioid-containing approaches in specific clinical contexts, and the centrality of individualized attending-level clinical judgment in all perioperative decision-making.

This educational review is intended to synthesize those themes for academic learning purposes. It does not resolve the clinical questions it discusses, advocate for specific approaches, or substitute for the expertise of the licensed clinicians who bear responsibility for perioperative care.

References

Full citations, with identity-checked PMIDs and DOIs (metadata only; see REFERENCE_AUDIT.md), are in the master list in 06_References.md. Sources cited in this document (master-list numbers):

[4] Albrecht et al., 2015 · [5] American Society of Anesthesiologists Task Force, 2014 · [6] An et al., 2023 · [7] Apfel et al., 1999 · [8] Ardon et al., 2022 · [10] Bashandy & Abbas, 2015 · [11] Beloeil, 2019 · [13] Blanco, 2011 · [14] Blanco et al., 2012 · [15] Blaudszun et al., 2012 · [18] Brinck et al., 2018 · [26] Gan et al., 2020 (historical) · [28] Horlocker et al., 2018 (historical) · [29] Hussain et al., 2019 · [31] Jacobs et al., 2020 (historical) · [33] Kehlet & Wilmore, 2008 · [34] Kim et al., 2018 · [37] McCarthy et al., 2010 · [40] Neal et al., 2018 · [41] Neal et al., 2021 · [51] Sun et al., 2020 · [52] Temple-Oberle et al., 2017 · [55] Vigneault et al., 2011 · [57] Weerink et al., 2017 · [58] White et al., 2007 · [60] American Society of Anesthesiologists Task Force, 2026 · [61] Desai et al., 2026 · [62] Foo et al., 2021 · [63] Gan et al., 2025 · [65] Kopp et al., 2025 · [66] Verret et al., 2020

Author and License

Collin B. George, pre-medical student ORCID: 0009-0007-8162-6839 GitHub: github.com/collingeorge

This is an independent scholarly work. It is not affiliated with, endorsed by, reviewed by, or issued on behalf of any healthcare, academic, or professional organization. All interpretations, conclusions, and any errors are solely the responsibility of the author.

Licensed under Creative Commons Attribution 4.0 International (CC BY 4.0).

Educational literature review only. Not intended for patient care, clinical decision-making, institutional implementation, or documentation use.